Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.

Yamaguchi A, Hirata S, Kubo S, Fukuyo S, Hanami K, Nakano K, Nakayamada S, Saito K, Tanaka Y.

Mod Rheumatol. 2019 Dec 7:1-23. doi: 10.1080/14397595.2019.1702141. [Epub ahead of print]

PMID:
31814496
2.

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Kitanaga Y, Imamura E, Nakahara Y, Fukahori H, Fujii Y, Kubo S, Nakayamada S, Tanaka Y.

Rheumatology (Oxford). 2019 Nov 25. pii: kez526. doi: 10.1093/rheumatology/kez526. [Epub ahead of print]

PMID:
31764973
3.
4.

Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10.

Tanaka K, Yamagata K, Kubo S, Nakayamada S, Sakata K, Matsui T, Yamagishi SI, Okada Y, Tanaka Y.

Bone. 2019 Nov;128:115034. doi: 10.1016/j.bone.2019.115034. Epub 2019 Aug 14.

PMID:
31421252
5.

Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis.

Kubo S, Nakayamada S, Miyazaki Y, Yoshikawa M, Yoshinari H, Satoh Y, Todoroki Y, Nakano K, Satoh M, Smith V, Cutolo M, Tanaka Y.

Rheumatology (Oxford). 2019 Dec 1;58(12):2273-2283. doi: 10.1093/rheumatology/kez244.

PMID:
31230071
6.

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.

Miyagawa I, Nakano K, Iwata S, Nakayamada S, Saito K, Hanami K, Fukuyo S, Kubo S, Kawabe A, Miyazaki Y, Tanaka Y.

Arthritis Res Ther. 2019 Jun 22;21(1):151. doi: 10.1186/s13075-019-1933-8.

7.

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases.

Tanaka Y, Kubo S, Miyagawa I, Iwata S, Nakayamada S.

Semin Arthritis Rheum. 2019 Jun;48(6):1146-1150. doi: 10.1016/j.semarthrit.2019.04.007. Epub 2019 Apr 25.

PMID:
31079846
8.

Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.

Kubo S, Nakayamada S, Tanaka Y.

Expert Rev Clin Immunol. 2019 Jul;15(7):693-700. doi: 10.1080/1744666X.2019.1608821. Epub 2019 Apr 25.

PMID:
30987474
9.

IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2.

Kurozumi A, Nakano K, Yamagata K, Okada Y, Nakayamada S, Tanaka Y.

Bone. 2019 Jul;124:53-61. doi: 10.1016/j.bone.2019.04.006. Epub 2019 Apr 11.

PMID:
30981888
10.

Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine.

Miyagawa I, Nakayamada S, Tanaka Y.

Curr Rheumatol Rep. 2019 Mar 20;21(5):21. doi: 10.1007/s11926-019-0817-x. Review.

PMID:
30891646
11.

Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance.

Okabe Y, Aoki T, Terasawa T, Kinoshita S, Nakayamada S, Tanaka Y, Korogi Y.

Clin Imaging. 2019 May - Jun;55:140-143. doi: 10.1016/j.clinimag.2019.02.014. Epub 2019 Feb 20.

PMID:
30818164
12.

Janus kinases to jakinibs: from basic insights to clinical practice.

Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O'Shea JJ.

Rheumatology (Oxford). 2019 Feb 1;58(Supplement_1):i4-i16. doi: 10.1093/rheumatology/key432.

13.

Radiological patterns of pulmonary involvement may predict treatment response in rheumatoid arthritis: A retrospective study.

Hanaka T, Kido T, Ishimoto H, Oda K, Noguchi S, Nawata A, Nakayamada S, Sakamoto N, Tanaka Y, Yatera K, Mukae H.

Respir Investig. 2019 Mar;57(2):172-182. doi: 10.1016/j.resinv.2018.12.006. Epub 2019 Feb 1.

PMID:
30718103
14.

Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis.

Miyazaki Y, Nakayamada S, Kubo S, Nakano K, Iwata S, Miyagawa I, Ma X, Trimova G, Sakata K, Tanaka Y.

Front Immunol. 2018 Dec 10;9:2901. doi: 10.3389/fimmu.2018.02901. eCollection 2018.

15.

Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus.

Yoshikawa M, Nakayamada S, Kubo S, Nawata A, Kitanaga Y, Iwata S, Sakata K, Ma X, Wang SP, Nakano K, Saito K, Tanaka Y.

Clin Immunol. 2019 Mar;200:1-9. doi: 10.1016/j.clim.2018.12.017. Epub 2018 Dec 19.

PMID:
30576845
16.

An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis.

Ueno M, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Tanaka Y.

Intern Med. 2019 Apr 1;58(7):1023-1027. doi: 10.2169/internalmedicine.1226-18. Epub 2018 Dec 18.

17.

Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis.

Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050. doi: 10.1073/pnas.1808850115. Epub 2018 Nov 29.

18.

Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis.

Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Yamagata K, Hirata S, Sakata K, Todoroki Y, Nakano K, Nakayamada S, Satoh M, Tanaka Y.

Arthritis Res Ther. 2018 Oct 26;20(1):240. doi: 10.1186/s13075-018-1737-2.

19.

Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.

Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, Kubo S, Inoue Y, Ueno M, Tanaka Y.

Int J Rheum Dis. 2019 Mar;22(3):434-442. doi: 10.1111/1756-185X.13387. Epub 2018 Oct 18.

PMID:
30338639
20.

Immunophenotype involved in IgG4-related disease.

Kubo S, Nakayamada S, Tanaka Y.

Mod Rheumatol. 2019 Mar;29(2):226-230. doi: 10.1080/14397595.2018.1537962. Epub 2019 Jan 9. Review.

PMID:
30334637
21.

Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.

Sakata K, Nakayamada S, Miyazaki Y, Kubo S, Ishii A, Nakano K, Tanaka Y.

Front Immunol. 2018 Aug 28;9:1957. doi: 10.3389/fimmu.2018.01957. eCollection 2018.

22.

Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies.

Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, Satoh Y, Miyagawa I, Saito K, Smith V, Cutolo M, Tanaka Y.

Rheumatology (Oxford). 2019 Jan 1;58(1):120-130. doi: 10.1093/rheumatology/key257.

PMID:
30169697
23.

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System.

Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, Ishii A, Yamagata K, Nakano K, Tanaka Y.

Front Immunol. 2018 Jun 28;9:1510. doi: 10.3389/fimmu.2018.01510. eCollection 2018.

24.

Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.

Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y.

Clin Immunol. 2018 Oct;195:1-7. doi: 10.1016/j.clim.2018.07.003. Epub 2018 Jul 4.

PMID:
29981383
25.

Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.

Ma X, Nakayamada S, Kubo S, Sakata K, Yamagata K, Miyazaki Y, Yoshikawa M, Kitanaga Y, Zhang M, Tanaka Y.

Ann Rheum Dis. 2018 Sep;77(9):1354-1361. doi: 10.1136/annrheumdis-2017-212652. Epub 2018 May 31.

PMID:
29853448
26.
27.

Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis.

Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, Yoshikawa M, Yoshinari H, Tanaka Y.

Rheumatology (Oxford). 2019 Feb 1;58(2):336-344. doi: 10.1093/rheumatology/key069.

PMID:
29618121
28.

Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching.

Kubo S, Nakayamada S, Nakano K, Sawamukai N, Hirata S, Hanami K, Saito K, Tanaka Y.

Clin Immunol. 2018 Jun;191:67-74. doi: 10.1016/j.clim.2018.03.018. Epub 2018 Mar 31.

PMID:
29614335
29.

Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair.

Yamagata K, Nakayamada S, Tanaka Y.

Inflamm Regen. 2018 Mar 12;38:4. doi: 10.1186/s41232-018-0061-1. eCollection 2018. Review.

30.

IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion.

Nagayasu A, Kubo S, Nakano K, Nakayamada S, Iwata S, Miyagawa I, Fukuyo S, Saito K, Tanaka Y.

Intern Med. 2018 Aug 1;57(15):2251-2257. doi: 10.2169/internalmedicine.0387-17. Epub 2018 Mar 9.

31.

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.

Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y.

Lupus. 2018 Jun;27(7):1202-1206. doi: 10.1177/0961203318762598. Epub 2018 Mar 9.

PMID:
29523055
32.

Intracranial vessel wall lesions in patients with systematic lupus erythematosus.

Ide S, Kakeda S, Miyata M, Iwata S, Ohkubo N, Nakayamada S, Futatsuya K, Watanabe K, Moriya J, Fujino Y, Tanaka Y, Korogi Y.

J Magn Reson Imaging. 2018 Nov;48(5):1237-1246. doi: 10.1002/jmri.25966. Epub 2018 Feb 23.

PMID:
29473985
33.

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y.

Lupus. 2018 Apr;27(5):802-811. doi: 10.1177/0961203317749047. Epub 2018 Jan 7.

PMID:
29308726
34.

Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells.

Miyagawa I, Nakayamada S, Kondo M, Tanaka Y.

Crit Rev Immunol. 2018;38(6):471-478. doi: 10.1615/CritRevImmunol.2018027821. Review.

PMID:
31002601
35.

Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease.

Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, Hirata S, Nakano K, Saito K, Tanaka Y.

Rheumatology (Oxford). 2018 Mar 1;57(3):514-524. doi: 10.1093/rheumatology/kex455.

PMID:
29253269
36.

Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).

Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T.

Mod Rheumatol. 2018 Jul;28(4):642-648. doi: 10.1080/14397595.2017.1385154. Epub 2017 Nov 9.

PMID:
29120258
37.

Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus.

Miyata M, Kakeda S, Iwata S, Nakayamada S, Ide S, Watanabe K, Moriya J, Tanaka Y, Korogi Y.

Sci Rep. 2017 Oct 3;7(1):12566. doi: 10.1038/s41598-017-12966-4.

38.

B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus.

Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S.

Clin Immunol. 2018 Jan;186:21-25. doi: 10.1016/j.clim.2017.07.010. Epub 2017 Aug 5.

PMID:
28789968
39.

Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells.

Miyagawa I, Nakayamada S, Nakano K, Yamagata K, Sakata K, Yamaoka K, Tanaka Y.

J Immunol. 2017 Sep 1;199(5):1616-1625. doi: 10.4049/jimmunol.1600230. Epub 2017 Jul 19.

40.

Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells.

Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y.

Thyroid. 2017 Oct;27(10):1335-1336. doi: 10.1089/thy.2017.0062. Epub 2017 Aug 3. No abstract available.

PMID:
28699391
41.

Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells.

Torigoe M, Iwata S, Nakayamada S, Sakata K, Zhang M, Hajime M, Miyazaki Y, Narisawa M, Ishii K, Shibata H, Tanaka Y.

J Immunol. 2017 Jul 15;199(2):425-434. doi: 10.4049/jimmunol.1601908. Epub 2017 Jun 16.

42.

Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients.

Kubo S, Nakayamada S, Yoshikawa M, Miyazaki Y, Sakata K, Nakano K, Hanami K, Iwata S, Miyagawa I, Saito K, Tanaka Y.

Arthritis Rheumatol. 2017 Oct;69(10):2029-2037. doi: 10.1002/art.40180. Epub 2017 Aug 25.

43.

Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.

Fukuyo S, Nakayamada S, Iwata S, Kubo S, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2017 Jul-Aug;35(4):562-570. Epub 2017 Apr 27.

PMID:
28516880
44.

Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis.

Nakayamada S, Kubo S, Yoshikawa M, Miyazaki Y, Yunoue N, Iwata S, Miyagawa I, Hirata S, Nakano K, Saito K, Tanaka Y.

Rheumatology (Oxford). 2018 Jan 1;57(1):164-174. doi: 10.1093/rheumatology/kex012.

PMID:
28371836
45.

Erratum to: Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

BioDrugs. 2016 Oct;30(5):483. No abstract available.

PMID:
27699710
46.

Chemical JAK inhibitors for the treatment of rheumatoid arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

Expert Opin Pharmacother. 2016 Nov;17(16):2215-2225. doi: 10.1080/14656566.2016.1241237. Epub 2016 Oct 8.

PMID:
27690665
47.

Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.

Kubo S, Nakano K, Nakayamada S, Hirata S, Fukuyo S, Sawamukai N, Saito K, Tanaka Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5):834-841. Epub 2016 Aug 31.

PMID:
27607196
48.

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

BioDrugs. 2016 Oct;30(5):407-419. Review. Erratum in: BioDrugs. 2016 Oct;30(5):483.

PMID:
27577235
49.

BAFF- and APRIL-targeted therapy in systemic autoimmune diseases.

Nakayamada S, Tanaka Y.

Inflamm Regen. 2016 Jul 21;36:6. doi: 10.1186/s41232-016-0015-4. eCollection 2016. Review.

50.

Baricitinib for the treatment of rheumatoid arthritis.

Kubo S, Nakayamada S, Tanaka Y.

Expert Rev Clin Immunol. 2016 Sep;12(9):911-9. doi: 10.1080/1744666X.2016.1214576. Epub 2016 Aug 5. Review.

PMID:
27427830

Supplemental Content

Loading ...
Support Center